OS-060-YI Phase III trials in hepatocellular carcinoma: IMbrave 050 and strategies to address non-proportional hazards

Ezequiel Mauro; Tiago B. R. Castro; Marcus Zeitlhoefler; Allan Hackshaw; MinJae Lee; Tim Meyer; Amit Singal; Josep M. Llovet

doi:10.1016/s0168-8278(25)00375-7

Related publications

Article2025

Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Ezequiel Mauro, Tiago B. R. Castro, Marcus Zeitlhoefler, Allan Hackshaw, MinJae Lee, Tim Meyer, Amit G. Singal, Josep M. Llovet

Article2020

IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation

Stephen P. Hack, Jessica Spahn, Minshan Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Pierce K. H. Chow, Shukui Qin

Article2017

Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)

Liping Huang, Yoriko De Sanctis, Minghua Shan, Jordi Bruix, Josep M. Llovet, Ann‐Lii Cheng, Gudrun Meinhardt, Keiko Nakajima

Annals of Oncology

Article2008

Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

Josep M. Llovet, Gregory J. Gores

JNCI Journal of the National Cancer Institute

Article2025

THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Martí Torres-Marcen, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, David Camell, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ieva Keraite, Roger Esteban-Fabró, Takayuki Kimura, Alka A. Potdar, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Daniela Sia, Roser Pinyol, Josep M. Llovet